Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2006 2
2007 1
2008 1
2009 2
2011 1
2012 1
2013 1
2014 1
2015 2
2016 2
2017 2
2018 2
2019 3
2020 2
2021 5
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

30 results
Results by year
Filters applied: . Clear all
Page 1
Fc-Independent Protection from SARS-CoV-2 Infection by Recombinant Human Monoclonal Antibodies.
Noy-Porat T, Edri A, Alcalay R, Makdasi E, Gur D, Aftalion M, Evgy Y, Beth-Din A, Levy Y, Epstein E, Radinsky O, Zauberman A, Lazar S, Yitzhaki S, Marcus H, Porgador A, Rosenfeld R, Mazor O. Noy-Porat T, et al. Among authors: zauberman a. Antibodies (Basel). 2021 Nov 8;10(4):45. doi: 10.3390/antib10040045. Antibodies (Basel). 2021. PMID: 34842604 Free PMC article.
Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice.
Noy-Porat T, Mechaly A, Levy Y, Makdasi E, Alcalay R, Gur D, Aftalion M, Falach R, Leviatan Ben-Arye S, Lazar S, Zauberman A, Epstein E, Chitlaru T, Weiss S, Achdout H, Edgeworth JD, Kikkeri R, Yu H, Chen X, Yitzhaki S, Shapira SC, Padler-Karavani V, Mazor O, Rosenfeld R. Noy-Porat T, et al. Among authors: zauberman a. iScience. 2021 May 21;24(5):102479. doi: 10.1016/j.isci.2021.102479. Epub 2021 Apr 26. iScience. 2021. PMID: 33937725 Free PMC article.
Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody.
Rosenfeld R, Noy-Porat T, Mechaly A, Makdasi E, Levy Y, Alcalay R, Falach R, Aftalion M, Epstein E, Gur D, Chitlaru T, Vitner EB, Melamed S, Politi B, Zauberman A, Lazar S, Beth-Din A, Evgy Y, Yitzhaki S, Shapira SC, Israely T, Mazor O. Rosenfeld R, et al. Among authors: zauberman a. Nat Commun. 2021 Feb 11;12(1):944. doi: 10.1038/s41467-021-21239-8. Nat Commun. 2021. PMID: 33574228 Free PMC article.
Early Diagnosis of Pathogen Infection by Cell-Based Activation Immunoassay.
Bar-Haim E, Rotem S, Elia U, Bercovich-Kinori A, Israeli M, Cohen-Gihon I, Israeli O, Erez N, Achdout H, Zauberman A, Aftalion M, Mamroud E, Chitlaru T, Cohen O. Bar-Haim E, et al. Among authors: zauberman a. Cells. 2019 Aug 22;8(9):952. doi: 10.3390/cells8090952. Cells. 2019. PMID: 31443439 Free PMC article.
A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes.
Noy-Porat T, Makdasi E, Alcalay R, Mechaly A, Levy Y, Bercovich-Kinori A, Zauberman A, Tamir H, Yahalom-Ronen Y, Israeli M, Epstein E, Achdout H, Melamed S, Chitlaru T, Weiss S, Peretz E, Rosen O, Paran N, Yitzhaki S, Shapira SC, Israely T, Mazor O, Rosenfeld R. Noy-Porat T, et al. Among authors: zauberman a. Nat Commun. 2020 Aug 27;11(1):4303. doi: 10.1038/s41467-020-18159-4. Nat Commun. 2020. PMID: 32855401 Free PMC article.
Phage Therapy Potentiates Second-Line Antibiotic Treatment against Pneumonic Plague.
Vagima Y, Gur D, Aftalion M, Moses S, Levy Y, Makovitzki A, Holtzman T, Oren Z, Segula Y, Fatelevich E, Tidhar A, Zauberman A, Rotem S, Mamroud E, Steinberger-Levy I. Vagima Y, et al. Among authors: zauberman a. Viruses. 2022 Mar 26;14(4):688. doi: 10.3390/v14040688. Viruses. 2022. PMID: 35458417 Free PMC article.
Influenza virus infection augments susceptibility to respiratory Yersinia pestis exposure and impacts the efficacy of antiplague antibiotic treatments.
Vagima Y, Gur D, Erez N, Achdout H, Aftalion M, Levy Y, Zauberman A, Tidhar A, Gutman H, Lazar S, Israely T, Paran N, Melamed S, Brosh-Nissimov T, Chitlaru T, Sagi I, Mamroud E. Vagima Y, et al. Among authors: zauberman a. Sci Rep. 2020 Nov 5;10(1):19116. doi: 10.1038/s41598-020-75840-w. Sci Rep. 2020. PMID: 33154422 Free PMC article.
30 results